Read about different genes that are linked to hereditary cancer, their associated risks and guidelines for screening, preventing and treating cancers in people with inherited mutations in these genes.
Cancer treatment for people with MAP
Currently there are no cancer treatments approved specifically for people with MAP, however, clinical trials looking at new types of treatment may be available in the future. Colorectal cancers in people with MAP often have an acquired mutation called KRAS G12C, and there are clinical trials investigating new medications to treat colorectal cancers with this specific KRAS mutation. To learn more about standard of care treatment options for specific types of cancer, visit our section on Cancer Treatment by Cancer Type.
The following studies are open to people with colorectal cancer with a KRAS G12C mutation. These mutations are particularly common in people with MAP.
- NCT04793958: Phase 3 Study of the drug MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10). This study will compare the effectiveness of the agent MRTX849 in combination with cetuximab versus chemotherapy as second-line treatment for patients with CRC with KRAS G12C mutation.
- NCT04449874: A Study to Evaluate the Safety and Activity of the drug GDC-6036 Alone or in Combination in Participants With Advanced or Solid Tumors With a KRAS G12C Mutation. This study will evaluate the safety and activity of the drug GDC-6036 in patients with advanced or solid tumors with a KRAS G12C mutation.
- NCT04699188: Study of JDQ443 in Patients With Advanced Solid Tumors with a KRAS G12C Mutation. This study will look at the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other treatments in advanced solid tumor patients.
- NCT03785249: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation.
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced that have a KRAS G12C mutation.